The Covid effect has triggered some radical changes to the top 50 biopharma list, bringing a whole new group of players into the big league
Back on March 11 last year, the biopharma world was going into a global lockdown. The pandemic was officially hitting the US, and a broad fear had settled in on the realization that this time around, after years of pandemic fears, we were really in for it. Wall Street shivered in fear.
Then the upside became clear, and the Covid-19 effect proceeded to completely revamp the list of top biopharma firms by market cap in remarkable ways.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.